Cost-Effectiveness of Disease- Modifying Therapies in Multiple Sclerosis: A Managed Care Perspective
Advertisement
Advertisement
Trending on AJMC
1
FDA to Accept Deidentified Real-World Evidence for Select Medical Device Applications
2
COVID-19 Vaccination in Pregnant Patients Reduces Hospitalization, Preterm Birth Across Variants
3
FDA Approves Fam-Trastuzumab Deruxtecan-Nxki for Metastatic HER2-Positive Breast Cancer
4
Orlowski Calls Linvoseltamab Results “the Best Single-Agent Data Ever in the History of Myeloma”
5
